Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM ESTCompany ParticipantsAndrew Dickinson - Chief ...
Researchers are increasingly developing antibody therapies to treat infectious diseases. Therapies are being designed to reduce the severity of infections such as bird flu, and cure HIV and other ...
(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) Robin Lin Miller, Michigan State University (THE CONVERSATION) Protecting public ...
(THE CONVERSATION) Protecting public health abroad benefits Americans. In a globalized world, diseases and their social and economic impacts do not stay within national boundaries. Increased rates of ...
Zacks Investment Research on MSN
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
Gilead Sciences, Inc.’s GILD posted 3% year-over-year growth in total revenues for the third quarter of 2025. Total revenues comprise product sales and royalty, contract and other revenues. While ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback